Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Fibrogen Inc CS
(NQ:
FGEN
)
0.3655
-0.0045 (-1.22%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Fibrogen Inc CS
< Previous
1
2
3
4
5
6
7
Next >
FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial
August 11, 2021
The FDA has issued a complete response letter regarding the marketing application for FibroGen Inc's (NASDAQ: FGEN) roxadustat for anemia of chronic kidney disease...
Via
Benzinga
Exposures
Product Safety
10 Biggest Price Target Changes For Tuesday
August 10, 2021
Rosenblatt raised the price target on The Trade Desk, Inc. (NASDAQ:
Via
Benzinga
FibroGen, inc (FGEN) Q2 2021 Earnings Call Transcript
August 10, 2021
FGEN earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
August 08, 2021
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...
Via
Benzinga
Exposures
Product Safety
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
August 02, 2021
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges...
Via
Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
July 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...
Via
Benzinga
Exposures
COVID-19
What's Next for FibroGen After an FDA Vote Against Its Anemia Drug?
July 29, 2021
FDA approval of roxadustat seems unlikely.
Via
The Motley Fool
Topics
Cannabis
Exposures
Cannabis
Product Safety
Week In Review: Qiming Launches $500 Million Fund For Listed Healthcare Companies
July 24, 2021
Qiming, a prominent China-based venture capital firm, has raised more than $500 million to invest in shares of listed healthcare companies. The Springhill Fund, as it is called, will have an initial...
Via
Talk Markets
FibroGen Out-Licenses Recombinant Human Collagen-Based Biosynthetic Cornea
July 19, 2021
Eluminex Biosciences (Suzhou) Limited has exclusively licensed global rights to develop and commercialize a biosynthetic cornea from FibroGen Inc (NASDAQ:...
Via
Benzinga
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
July 18, 2021
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week stoked rate hike fears,...
Via
Talk Markets
Exposures
Product Safety
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
July 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI...
Via
Benzinga
50 Biggest Movers From Friday
July 19, 2021
Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares jumped 41.2% to settle at $7.10 on Friday. Blue Foundry Bancorp (NASDAQ: BLFY) gained 29% to close at $12.90 after the...
Via
Benzinga
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
July 18, 2021
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week...
Via
Benzinga
Exposures
Product Safety
Mid-Afternoon Market Update: Dow Tumbles Over 200 Points; Aehr Test Systems Shares Spike Higher
July 16, 2021
Toward the end of trading Friday, the Dow traded down 0.63% to 34,766.06 while the NASDAQ fell 0.47% to 14,475.13. The S&P also fell, dropping 0.53% to 4,336.88. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Here's Why FibroGen Stock Is Plunging Today
July 16, 2021
An FDA advisory committee made it clear that they don't want the agency to approve roxadustat due to safety concerns.
Via
The Motley Fool
Exposures
Product Safety
Stocks Reverse Gains as Inflation Fears Weigh
July 16, 2021
Stocks reversed earlier gains brought on by strong retail sales data and mixed earnings reports, as worse-than-expected inflation findings weighed on Wall Street.
Via
Talk Markets
FibroGen Analyst Removes Roxadustat Sales From Model After AdCom Snub
July 16, 2021
FibroGen, Inc. (NASDAQ:FGEN) shares were slumping over 40%...
Via
Benzinga
33 Stocks Moving In Friday's Mid-Day Session
July 16, 2021
Gainers TD Holdings, Inc. (NASDAQ: GLG) jumped 49% to $1.21 after the company entered a non-binding letter of intent to acquire Guangdong Jinbochuang Special Purpose Vehicle Co....
Via
Benzinga
Analyzing FibroGen's Unusual Options Activity
July 16, 2021
Shares of FibroGen (NASDAQ:FGEN) saw some unusual options activity on Friday. Following the unusual option alert, the stock price moved down to $13.83. Sentiment: BEARISH Option...
Via
Benzinga
FGEN Stock: The Huge FDA News Causing FibroGen Shares to Free Fall
July 16, 2021
FibroGen (FGEN) stock is falling hard on Friday after the company received the results of an FDA review for one of its drugs.
Via
InvestorPlace
Exposures
Product Safety
Mid-Morning Market Update: Markets Down; Kansas City Southern Earnings Miss Views
July 16, 2021
Following the market opening Friday, the Dow traded down 0.41% to 34,844.89 while the NASDAQ fell 0.30% to 14,499.54. The S&P also fell, dropping 0.30% to 4,346.93. The U.S....
Via
Benzinga
Topics
Earnings
Stocks
Exposures
Financial
US Equities
Why FibroGen's Stock Is Getting Hammered Today
July 16, 2021
FibroGen, Inc. (NASDAQ: FGEN) shares are trading lower after an FDA Advisory Committee panel voted against approval of the company's New Drug Application for roxadustat to...
Via
Benzinga
Exposures
Product Safety
FibroGen Stock Collapses After FDA Panel Rejects Anemia Treatment
July 16, 2021
A FDA panel voted resoundingly against recommending approval for an anemia treatment from FibroGen, and FGEN stock tanked on Friday.
Via
Investor's Business Daily
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For July 16, 2021
July 16, 2021
Upgrades According to Citigroup, the prior rating for Alcoa Corp (NYSE:
Via
Benzinga
GlaxoSmithKline's Anemia Candidate Shows Promise In Late-Stage Studies
July 16, 2021
GlaxoSmithKline Plc (NYSE: GSK) said its anemia drug for patients with chronic kidney disease succeeded in five late-stage trials. The drug, daprodustat, an oral...
Via
Benzinga
10 Biggest Price Target Changes For Friday
July 16, 2021
Credit Suisse raised Cintas Corporation (NASDAQ: CTAS) price target from $350 to $375. Cintas shares rose 1.4% to $374.12 in pre-market trading. Barclays raised the price target...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
July 16, 2021
Gainers Moderna (NASDAQ:MRNA) stock increased by 7.67% to $279.6 during Friday's pre-market session. The company's market cap stands at $112.2 billion. Eton...
Via
Benzinga
22 Stocks Moving in Friday's Pre-Market Session
July 16, 2021
Gainers Aehr Test Systems (NASDAQ: AEHR) shares rose 25.3% to $3.52 in pre-market trading after the company reported better-than-expected Q4 results and issued strong FY22 sales...
Via
Benzinga
FibroGen Staring At Multi-Year Lows Following Adverse Roxadustat AdCom Verdict; How Hard Will The Stock Likely Fall?
July 16, 2021
FibroGen, Inc.’s (NASDAQ: FGEN) shares are sinking to their lowest level since late June 2016. FibroGen’s AdCom Snub FibroGen said late Thursday the...
Via
Benzinga
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
July 15, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals,...
Via
Benzinga
Topics
Product Recall
Exposures
Legal
Product Safety
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.